139962-96-2

Upstream product

• 100-44-7 benzyl chloride 
• 2973-80-0 2-bromo-5-hydroxybenzaldehyde 
• 85604-06-4 5-(benzyloxy)-2-bromobenzaldehyde 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 139962-97-3 3-Benzyloxy-6-boronobenzaldehyde diethyl acetal 
• 1187190-70-0 1,3-dihydro-1,5-dihydroxy-2,1-benzoxaborolane 

Relevant academic research and scientific papers

Preparation method for creboro intermediate

The invention discloses a preparation method for a creboro intermediate. The preparation method for the creboro intermediate comprises the following steps that 1, 2-bromo-5-hydroxybenzaldehyde reactswith benzyl chloride or benzyl bromide in an organic solvent (i) under the existence of alkali to obtain a compound shown in a formula II; 2, the compound shown in the formula II reacts with triethylorthoformate or trimethyl orthoformate or glycol in an organic solvent (ii) under the effect of an acid catalyst to obtain a compound shown in a formula III; 3, 2-methoxyl-4, 4, 5, 5-tetramethyl-1, 3,2-boron dioxane or 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-boron dioxane or trimethyl borate or triisopropyl borate reacts with a standby solution in an organic solvent (iii) under the condition thatthe reaction temperature is 10-30 DEG C, after the reaction is completed, hydrochloric acid is added for regulating the pH value to be not larger than 3, and after a quenching reaction is performed, acompound shown in a formula IV is obtained through the reaction under the temperature of 20-100 DEG C.

Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores

Factor VIIa (FVIIa), a serine protease enzyme, coupled with tissue factor (TF) plays an important role in a number of thrombosis-related disorders. Inhibition of TF·FVIIa occurs early in the coagulation cascade and might provide some safety advantages over other related enzymes. We report here a novel series of substituted biphenyl derivatives that are highly potent and selective TF·FVIIa inhibitors. Parallel synthesis coupled with structure-based drug design allowed us to explore the S2 pocket of the enzyme active site. A number of compounds with IC50 value of 10 nM were synthesized. The X-ray crystal structures of some of these compounds complexed with TF·FVIIa were determined and results were applied to design the next round of inhibitors. All the potent inhibitors were tested for inhibition against a panel of related enzymes and selectivity of 17,600 over thrombin, 450 over trypsin, 685 over FXa, and 76 over plasmin was achieved. Two groups, vinyl 36b and 2-furan 36ab, were identified as the optimum binding substituents on the phenyl ring in the S2 pocket. Compounds with these two substituents are the most potent compounds in this series with good selectivity over related serine proteases. These compounds will be further explored for structure-activity relationship.

Total synthesis of plagiochins C, and D, macrocyclic bis(bibenzyl) constituents of plagiochila acantophylla

Plagiochins C (3) and D (4) were synthesized by convergent schemes. Rings C and B were joined by Ullman ether synthesis, the aryl-aryl bond between rings A and D was formed by Pd(0)-catalysed coupling of an arylboronic acid (ring D) and a bromobenzoic ester (ring A). Rings C and D were linked by the Wittig reaction, while final ring closure was effected by tetraphenylethene assisted Wurtz reaction.